KROS - Keros Therapeutics reports preclinical data from hematology programs

Keros Therapeutics (KROS) announces results from preclinical studies of KER-050 and its ALK2 inhibitor program at the virtual European School of Haematology held from March 5 through 7, 2021. Keros has previously shown that mice treated with a single 10 mg/kg dose of a research form of KER-050 had increased red blood cells (“RBCs”, +7%), hemoglobin (“HGB”, +6.7%) and reticulocytes (“RET”, +20%) as soon as 12 hours after administration compared to vehicle-treated mice. A single dose of RKER-050 increased RBCs and HGB through at least Day 51 (+8.5% and +3%, respectively). Concurrently, despite increased erythropoiesis, erythropoietin levels were greater than two-fold higher than controls, starting at Day 4, continuing through Day 37 and returning to baseline by Day 51. These results have been further explored using a mouse model of anemia of inflammation via induced chronic kidney disease.In this preclinical study, mice were dosed daily for six weeks with 50

For further details see:

Keros Therapeutics reports preclinical data from hematology programs